Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

54.20
+1.793.41%
Volume:10.53M
Turnover:567.59M
Market Cap:110.33B
PE:18.24
High:54.28
Open:53.40
Low:53.01
Close:52.41
52wk High:63.33
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.22
T/O Rate:0.52%
Dividend:2.48
Dividend Rate:4.57%
EPS(TTM):2.97
EPS(LYR):-4.4144
ROE:33.78%
ROA:9.39%
PB:5.95
PE(LYR):-12.28

Loading ...

Market Chatter: Metsera Had Talks With Bristol-Myers Prior to Pfizer, Novo Nordisk Bids

MT Newswires Live
·
Oct 31

Stock Track | Bristol-Myers Squibb Soars 5.23% on Strong Q3 Earnings, Raised Guidance

Stock Track
·
Oct 30

Bristol-Myers Squibb Exec Says Sales of Reblozyl Annualizing at Over $2 Bln, Breyanzi at Over $1 Bln and Camzyos at Over $1 Bln - Conf Call

THOMSON REUTERS
·
Oct 30

Earnings Flash (BMY) Bristol-Myers Squibb Posts Q3 Revenue $12.2B, vs. FactSet Est of $11.81B

MT Newswires Live
·
Oct 30

Bristol-Myers Squibb Q3 Adj. EPS $1.63 Beats $1.51 Estimate, Sales $12.222B Beat $11.814B Estimate

Benzinga
·
Oct 30

Bristol Myers beats quarterly revenue estimates on strong Opdivo sales

Reuters
·
Oct 30

Press Release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

Dow Jones
·
Oct 30

Bristol Myers Q3 REV $12.22 Bln VS Ibes Estimate $11.81 Bln

THOMSON REUTERS
·
Oct 30

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 30

Will Positive Sotyktu Phase 3 Data Transform Bristol Myers Squibb's (BMY) Immunology Growth Narrative?

Simply Wall St.
·
Oct 30

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Oct 29

Bristol-Myers Squibb’s Phase 3 Alzheimer’s Study: A Potential Game-Changer?

TIPRANKS
·
Oct 28

Bristol Myers Squibb Co. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Oct 28

Bristol-Myers Squibb’s New Study on Nivolumab: Market Implications and Progress

TIPRANKS
·
Oct 28

Bristol-Myers Squibb Says New Data Show Efficacy of Sotyktu in Psoriatic Arthritis, Lupus

MT Newswires Live
·
Oct 27

Hold Rating for Bristol-Myers Squibb Amid Fair Valuation and Mixed Growth Prospects

TIPRANKS
·
Oct 27

Bristol Myers’ Sotyktu shows efficacy in arthritis and SLE

TIPRANKS
·
Oct 27